Related Experiment Videos
Heparin in clinical doses 'primes' granulocytes to subsequent activation as measured by myeloperoxidase release
1Surgical Department A, Institute for Surgical Research, The National Hospital, Oslo, Norway.
The author pre-incubated isolated human granulocytes with increasing doses of heparin (0-100 IU/mL) before subsequent stimulation with formyl-met-leu-phe. There was a dose-dependent increase in granulocyte activation as measured by myeloperoxidase release, quantitated in enzyme-immunoassay. This 'priming' effect of heparin was not due to activation of contaminating platelets or to endotoxin, and there was no reduction in granulocyte viability. Heparin-induced 'priming' of granulocytes may be clinically relevant in the setting of cardiopulmonary bypass. The author describes a sensitive and specific double antibody enzyme-immunoassay for myeloperoxidase from human granulocytes, with an inter-assay coefficient of variation of 12.6%, an intra-assay coefficient of variation of 4.3%, and a lower detection limit of 1.8 microg/l.
The author pre-incubated isolated human granulocytes with increasing doses of heparin (0-100 IU/mL) before subsequent stimulation with formyl-met-leu-phe. There was a dose-dependent increase in granulocyte activation as measured by myeloperoxidase release, quantitated in enzyme-immunoassay. This 'priming' effect of heparin was not due to activation of contaminating platelets or to endotoxin, and there was no reduction in granulocyte viability. Heparin-induced 'priming' of granulocytes may be clinically relevant in the setting of cardiopulmonary bypass. The author describes a sensitive and specific double antibody enzyme-immunoassay for myeloperoxidase from human granulocytes, with an inter-assay coefficient of variation of 12.6%, an intra-assay coefficient of variation of 4.3%, and a lower detection limit of 1.8 microg/l.